Allena Pharmaceuticals Inc (NASDAQ:ALNA) has earned an average recommendation of “Buy” from the ten research firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $29.57.
Several analysts recently issued reports on ALNA shares. Zacks Investment Research upgraded shares of Allena Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, January 14th. Robert W. Baird initiated coverage on Allena Pharmaceuticals in a report on Friday, January 18th. They issued an “outperform” rating and a $20.00 price target for the company. ValuEngine raised Allena Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, December 12th. Jefferies Financial Group initiated coverage on Allena Pharmaceuticals in a report on Thursday, November 8th. They issued a “buy” rating and a $22.00 price target for the company. Finally, B. Riley reaffirmed a “buy” rating and issued a $22.00 price target on shares of Allena Pharmaceuticals in a report on Friday, December 21st.
ALNA traded down $0.39 on Friday, hitting $6.83. 45,727 shares of the company’s stock were exchanged, compared to its average volume of 35,698. Allena Pharmaceuticals has a fifty-two week low of $4.80 and a fifty-two week high of $17.56. The company has a quick ratio of 14.75, a current ratio of 14.75 and a debt-to-equity ratio of 0.17. The stock has a market cap of $148.23 million, a PE ratio of -1.42 and a beta of 1.90.
Several institutional investors have recently added to or reduced their stakes in the company. Morgan Stanley increased its holdings in Allena Pharmaceuticals by 126.0% during the 3rd quarter. Morgan Stanley now owns 1,856,640 shares of the company’s stock worth $19,941,000 after purchasing an additional 1,034,990 shares during the last quarter. BlackRock Inc. raised its stake in Allena Pharmaceuticals by 145.1% during the 2nd quarter. BlackRock Inc. now owns 567,707 shares of the company’s stock valued at $7,397,000 after purchasing an additional 336,053 shares during the last quarter. Northern Trust Corp raised its stake in Allena Pharmaceuticals by 94.0% during the 2nd quarter. Northern Trust Corp now owns 113,981 shares of the company’s stock valued at $1,485,000 after purchasing an additional 55,238 shares during the last quarter. Sphera Funds Management LTD. raised its stake in Allena Pharmaceuticals by 16.9% during the 4th quarter. Sphera Funds Management LTD. now owns 345,199 shares of the company’s stock valued at $1,881,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Fosun International Ltd acquired a new position in Allena Pharmaceuticals during the 4th quarter valued at $154,000. Institutional investors and hedge funds own 84.60% of the company’s stock.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company’s lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Receive News & Ratings for Allena Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Allena Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.